NASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis $29.47 +0.13 (+0.44%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$30.16 +0.69 (+2.35%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IDEAYA Biosciences Stock (NASDAQ:IDYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IDEAYA Biosciences alerts:Sign Up Key Stats Today's Range$29.14▼$29.8350-Day Range$28.05▼$33.9152-Week Range$19.26▼$39.28Volume1.10 million shsAverage Volume731,002 shsMarket Capitalization$2.59 billionP/E RatioN/ADividend YieldN/APrice Target$50.69Consensus RatingModerate Buy Company Overview IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications. Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization. Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.AI Generated. May Contain Errors. Read More IDEAYA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreIDYA MarketRank™: IDEAYA Biosciences scored higher than 69% of companies evaluated by MarketBeat, and ranked 271st out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 15 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialIDEAYA Biosciences has a consensus price target of $50.69, representing about 72.0% upside from its current price of $29.47.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEAYA Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IDEAYA Biosciences are expected to grow in the coming year, from ($4.28) to ($3.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -18.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -18.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IDEAYA Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.98% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 13.96, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently decreased by 0.01%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.56 News SentimentIDEAYA Biosciences has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,648,000.00 in company stock, which represents 0.0636% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,648,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders4.70% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDYA Stock News HeadlinesIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29 at 6:00 AM | prnewswire.comIDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare ConferenceMay 26, 2026 | prnewswire.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 30 at 1:00 AM | Porter & Company (Ad)IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Lowered by Wall Street ZenMay 23, 2026 | americanbankingnews.comIDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comIDEAYA Biosciences Files New Shelf Registration StatementMay 11, 2026 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), IDEAYA Biosciences (IDYA)May 8, 2026 | theglobeandmail.comAssessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time ReviewMay 8, 2026 | finance.yahoo.comSee More Headlines IDYA Stock Analysis - Frequently Asked Questions How have IDYA shares performed this year? IDEAYA Biosciences' stock was trading at $34.57 on January 1st, 2026. Since then, IDYA shares have decreased by 14.8% and is now trading at $29.47. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($1.07) by $0.04. The business's quarterly revenue was down 39.4% on a year-over-year basis. When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' top institutional shareholders include Janus Henderson Group PLC (8.27%), Dimensional Fund Advisors LP (1.52%), Candriam S.C.A. (1.26%) and Bank of America Corp DE (1.07%). Insiders that own company stock include Yujiro S Hata, Jeffrey Stein, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White and Jason Throne. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings5/05/2026Today5/30/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IDYA's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IDYA CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for IDEAYA Biosciences$50.69 High Price Target$79.00 Low Price Target$30.00 Potential Upside/Downside+72.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.70 million Net MarginsN/A Pretax Margin-62.17% Return on Equity-14.24% Return on Assets-13.09% Debt Debt-to-Equity RatioN/A Current Ratio10.74 Quick Ratio10.74 Sales & Book Value Annual Sales$225.27 million Price / Sales11.49 Cash FlowN/A Price / Cash FlowN/A Book Value$10.67 per share Price / Book2.76Miscellaneous Outstanding Shares87,861,000Free Float83,732,000Market Cap$2.59 billion OptionableOptionable Beta-0.04 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:IDYA) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
